Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
Status:
Recruiting
Trial end date:
2026-03-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, single arm, prospective, intervention trial. Since cladribine can
enhance the biological activity and self-protection of cytarabine, giving cladribine and
cytarabine together may kill more cancer cells. 10 centers from South China Childhood
Leukaemia Collaborative Group carry out the SCCLG-M5-2022 regimen including two courses of
CLAG(cladribine, darubicin and cytarabine) in the induction period for the treatment of newly
dignosed acute monocytic leukemia (M5). The targeted drugs sorafenib is used for FLT3
positive acute monocytic leukemia to inhibit the serine / threonine kinase activity of FLT3.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators:
First Affiliated Hospital of Shantou University Medical College Guangzhou First People's Hospital Jiangxi Province Children's Hospital Maternal and Child Health Hospital of Foshan Second Xiangya Hospital of Central South University Southern Medical University, China The First Affiliated Hospital of Guangzhou Medical University The First Affiliated Hospital of Nanchang University Third Affiliated Hospital, Sun Yat-Sen University